Physician profile
Michael Mandel
NPI 1861463564
$589,034.61
in general payments reported to CMS, 2019-2025
31 companies · $132K in 2025
The $132K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114K · 2020: $46K · 2021: $66K · 2022: $57K · 2023: $112K · 2024: $62K · 2025: $132K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $259K · Travel and Lodging: $35K · Food and Beverage: $11K · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $259,350.00 |
| Travel and Lodging | $34,864.46 |
| Food and Beverage | $11,217.30 |
| Education | $130.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $567,182.31 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Sunovion Pharmaceuticals INC. | $10,542.48 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $4,091.82 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,560.89 | 2019-2025 | Ofev, Jascayd |
| Actelion Pharmaceuticals US, INC. | $675.27 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Regeneron Healthcare Solutions, INC. | $618.87 | 2019-2025 | Dupixent |
| Genzyme Corporation | $386.11 | 2019-2025 | |
| Viatris Specialty LLC | $291.68 | 2025 | Yupelri |
| Mylan Specialty L.P. | $205.18 | 2019-2024 | Yupelri |
| Grifols USA, LLC | $202.98 | 2019-2023 | Prolastin-C Liquid |
| Insmed, INC. | $148.64 | 2021-2025 | Arikayce, Brinsupri |
| Takeda Pharmaceuticals U.S.A., INC. | $138.16 | 2020-2022 | |
| Genentech USA, INC. | $111.71 | 2019-2022 | |
| Inspire Medical Systems, INC. | $111.51 | 2024 | Inspire |
| Amgen INC. | $106.30 | 2024-2025 | Tezspire |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $96.95 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $56.52 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.81 | 2019-2023 | |
| Philips North America LLC | $49.91 | 2022 | |
| Verona Pharma, INC. | $49.78 | 2025 | Ohtuvayre |
| Shire North American Group INC | $49.76 | 2019 | |
| Lilly USA, LLC | $44.79 | 2025 | Zepbound |
| Ethicon INC. | $44.07 | 2019 | |
| Electromed, INC. | $39.18 | 2021-2025 | Smartvest |
| Janssen Pharmaceuticals, INC | $38.00 | 2020 | |
| Mallinckrodt Hospital Products INC. | $36.25 | 2021 | |
| Portola Pharmaceuticals, LLC | $32.03 | 2019 | |
| Jazz Pharmaceuticals INC. | $22.10 | 2021 | |
| Advanced Respiratory, INC | $21.01 | 2021 | |
| Circassia INC. | $15.11 | 2020 | |
| Mallinckrodt Enterprises LLC | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mandel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.